

CITATION REPORT

List of articles citing

Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor- α therapy in inflammatory bowel disease

DOI: 10.1111/apt.12624

Alimentary Pharmacology and Therapeutics, 2014, 39, 447-58

Source: <https://exaly.com/paper-pdf/59395642/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
127	Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers. 2014 , 25, 757-61		14
126	An open label study to evaluate the safety and efficacy of intratympanic golimumab therapy in patients with autoimmune inner ear disease. 2014 , 35, 1515-21		12
125	Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 660-71	6.1	114
124	The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. <i>Gastroenterology Clinics of North America</i> , 2014 , 43, 525-41	4.4	34
123	Treatment algorithms in Crohn's - up, down or something else?. 2014 , 28, 473-83		25
122	The Mucosal Immune System and Gastrointestinal Inflammation. 2015 , 284-316		
121	Cancer and immunomodulators in inflammatory bowel diseases. 2015 , 21, 674-98		37
120	Infliximab "Top-Down" Strategy is Superior to "Step-Up" in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2015 , 60, 737-43	2.8	38
119	Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 1227-36	6.1	51
118	How are cancer and connective tissue diseases related to sarcoidosis?. 2015 , 21, 517-24		16
117	Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD. 2015 , 21, 428-35		9
116	Complications of biologics in inflammatory bowel disease. 2015 , 31, 296-302		15
115	How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11331-42	5.6	3
114	Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. 2015 , 2015, 832395		10
113	IBS-like symptoms in patients with ulcerative colitis. 2015 , 8, 101-9		24
112	Hidradenitis Suppurativa: A Guide for the Practicing Physician. 2015 , 90, 1679-93		20
111	Medical Therapy for Crohn Disease: The Present. 2015 , 35-48		

110	Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. 2015 , 148, 1035-1058.e3		251
109	Early investigational TNF receptor antagonists for the treatment of ulcerative colitis. 2015 , 24, 761-8		5
108	Anti-tumor necrosis factor- α therapy in uveitis. 2015 , 60, 575-89		65
107	Incidence, management, and course of cancer in patients with inflammatory bowel disease. 2015 , 9, 326-33		23
106	Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. 2015 , 94, e556		24
105	Combination therapy for the treatment of Crohn's disease. 2015 , 15, 1429-42		1
104	Biologic agents for IBD: practical insights. 2015 , 12, 537-45		196
103	Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. 2015 , 38, 869-88		12
102	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. 2015 , 9, 945-65		229
101	[Golimumab Therapy in Ulcerative Colitis]. 2016 , 67, 64-73		2
100	Large B-Cell Lymphoma in an Adolescent Patient With Interleukin-10 Receptor Deficiency and History of Infantile Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016 , 63, e15-7	2.8	26
99	Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. 2016 ,		1
98	Low-event-rate meta-analyses of clinical trials: implementing good practices. 2016 , 35, 2467-78		30
97	Cancer and inflammatory bowel disease in the elderly. 2016 , 48, 1105-11		23
96	Practical Approaches to "Top-Down" Therapies for Crohn's Disease. 2016 , 18, 35		10
95	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. 2016 , 10, 913-24		21
94	Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1246	6.1	
93	Immune Based Therapies for Inflammatory Bowel Disease. 2016 , 37-61		

92	Anti-TNF therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes. 2016 , 95, e5108	14
91	A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. 2016 , 15, 493-501	26
90	Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO. 2016 , 10, 216-25	73
89	Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan. 2016 , 46, 930-8	12
88	Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses. 2016 , 35, 1-18	41
87	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). 2017 , 49, 338-358	34
86	Treatment of hidradenitis suppurativa with intralesional photodynamic therapy with 5-aminolevulinic acid and 630nm laser beam. 2017 , 85, 241-246	21
85	Biológicos y cáncer: ¿una relación peligrosa?. 2017 , 16, 51-61	
84	Adalimumab therapy in a patient with Crohn's disease with a giant pelvic paraganglioma after chemotherapy. 2017 , 10, 250-254	1
83	Step-Up vs. Top-Down Approach in Crohn's Disease. 2017 , 481-489	
82	Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. 2017 , 29, 84-90	5
81	Case 14-2017: A Man with Pain and Swelling of the Left Calf and a Purpuric Rash. 2017 , 377, 601	
80	Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. 2017 , 318, 1679-1686	261
79	Cost-utility Analysis: Thiopurines Plus Endoscopy-guided Biological Step-up Therapy is the Optimal Management of Postoperative Crohn's Disease. 2017 , 23, 1930-1940	9
78	Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 389-400	6.1 206
77	Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. 2017 , 37, 25-37	9
76	Aggressive large-cell neuroendocrine carcinoma of the sigmoid colon in a patient with ulcerative colitis. 2017 , 2017,	2
75	Second Korean guidelines for the management of ulcerative colitis. <i>Intestinal Research</i> , 2017 , 15, 7-37	4.1 40

74	[Second Korean Guideline for the Management of Ulcerative Colitis]. 2017 , 69, 1-28		16
73	Neoplasia and Precursor Lesions of the Female Genital Tract in IBD: Epidemiology, Role of Immunosuppressants, and Clinical Implications. 2018 , 24, 510-531		9
72	The Mexican consensus on the diagnosis and treatment of ulcerative colitis. 2018 , 83, 144-167		14
71	Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update. 2018 , 19, 363-375		51
70	Outcomes of Perianal Fistulising Crohn's Disease Following Anti-TNF Treatment Discontinuation. 2018 , 24, 1107-1113		13
69	The Mexican consensus on the diagnosis and treatment of ulcerative colitis. 2018 , 83, 144-167		3
68	Cessation of Biologics: Can It Be Done?. 2018 , 141-162		
67	Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland. 2018 , 30, 1159-1167		6
66	Systematic review and meta-analysis on the association of tuberculosis in Crohn's disease patients treated with tumor necrosis factor- α inhibitors (Anti-TNF). <i>World Journal of Gastroenterology</i> , 2018 , 24, 2764-2775	5.6	21
65	Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. 2018 , 10, 203-213		6
64	Fistula-associated anal carcinoma in Crohn's disease. 2018 , 12, 917-925		14
63	Lymphoproliferative Disorders in Inflammatory Bowel Disease Patients: Is It the Drugs or the Disease. 2018 , 25, 175-178		2
62	Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. 2018 , 32-33, 43-47		20
61	An update on treatment of ulcerative colitis. 2019 , 7, 295-304		1
60	Lymphoma Risk and Screening in IBD. 2019 , 61-73		
59	Crohn's Disease and the Risk of Cancer. 2019 , 32, 305-313		3
58	Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn's disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience. 2019 , 13, 13-21		7
57	Orally Delivered Antisense Oligodeoxyribonucleotides of TNF- α Via Polysaccharide-Based Nanocomposites Targeting Intestinal Inflammation. 2019 , 8, e1801389		28

56	A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population. 2019 , 36, 607-624		3
55	Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De-Escalation in Adults With Inflammatory Bowel Diseases. 2019 , 106, 605-615		24
54	Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies. 2019 , 10, 247		10
53	Inflammation and Pancreatic Cancer: Focus on Metabolism, Cytokines, and Immunity. 2019 , 20,		104
52	Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 880-889	6.1	24
51	The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy. 2019 , 25, 998-1005		7
50	Usefulness of Thiopurine Monotherapy for Crohn's Disease in the Era of Biologics: A Long-Term Single-Center Experience. 2019 , 64, 875-879		4
49	Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 147-154	6.1	25
48	Characteristics of biological therapy in pediatric patients with Crohn's disease. 2019 , 19, 181-196		2
47	Minor cereals exhibit superior antioxidant effects on human epithelial cells compared to common wheat cultivars. 2019 , 85, 143-152		6
46	Managing Risks with Biologics. 2019 , 21, 1		26
45	Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment?. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284818817293	4-7	11
44	Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. 2019 , 53, e1-e11		23
43	Resolution of Metastatic Colon Cancer upon Withdrawal of Anti-TNF Therapy for Crohn's Disease. 2019 , 50, 665-667		1
42	Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis. 2020 , 55, 133-141		11
41	Crohn's Disease. 2020 , 739-753		
40	Safety considerations with biologics and new inflammatory bowel disease therapies. 2020 , 36, 257-264		4
39	Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease. 2020 , 18, 628-636		6

38	Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy. 2020 , 13, 339-350		11
37	Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. 2020 , 8, CD012328		1
36	Diffuse large B-cell lymphoma of the rectum in a patient with Crohn's disease. 2020 , 13,		1
35	Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review. 2021 , 15, 827-839		6
34	TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. 2021 , 15, 840-859		11
33	Changing Paradigms in the Management of the Elderly IBD Patient. 2021 , 283-300		
32	Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis. <i>Cancers</i> , 2021 , 13,	6.6	0
31	Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series. 2021 , 1		0
30	Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders. 2021 , 9, 430		
29	Efficacy and Safety of Anti-TNF Therapy for Uveitis Associated with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis. 2021 , 8, 711-727		1
28	Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. 2021 , 33, 670-679		4
27	De novo ulcerative colitis after kidney transplantation treated with infliximab. <i>CEN Case Reports</i> , 2021 , 10, 500-505	1	0
26	The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211023399	4.7	0
25	Parent Perspectives on Exclusive Enteral Nutrition for the Treatment of Pediatric Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020 , 71, 744-748	2.8	3
24	Anal Canal Adenocarcinoma in a Patient with Longstanding Crohn's Disease Arising From Rectal Mucosa that Migrated From a Previously Treated Rectovaginal Fistula. <i>American Journal of Case Reports</i> , 2016 , 17, 448-53	1.3	5
23	Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. <i>Annals of Gastroenterology</i> , 2016 , 29, 127-36	2.2	5
22	Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape. <i>World Journal of Gastroenterology</i> , 2019 , 25, 4158-4171	5.6	13
21	Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?. <i>World Journal of Gastroenterology</i> , 2020 , 26, 3712-3719	5.6	3

20	Combination therapy for inflammatory bowel disease. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2017 , 8, 103-113	3	21
19	A Case of Breast Cancer Following Infliximab Treatment for Treatment-Refractory Crohn's Disease. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2014 , 4, 104-106	1.6	
18	What Is the Best Possible Therapy for My Crohn's Disease? State-of-the-Art Therapy for Newly Diagnosed Crohn's Disease. 2015 , 59-71		
17	I Heard These Medications Give You Cancer. Is That True? Risks of Malignancy with IBD Therapy. 2015 , 135-140		
16	Tumor Necrosis Factor-alpha Antibodies in Fistulizing Crohn's Disease: An Updated Systematic Review and Meta-analysis. <i>Journal of Research in Pharmacy Practice</i> , 2017 , 6, 135-144	1.3	1
15	Female-Specific Cancer Risks and Screening in Inflammatory Bowel Disease. 2019 , 55-60		
14	Cancer. 2019 , 205-213		
13	Role of Inflammatory Cytokines in the Initiation and Progression of Pancreatic Cancer. 2019 , 133-156		1
12	Tumor necrosis factor- α inhibitor use in patients with malignancy: is it safe?. <i>Intestinal Research</i> , 2020 , 18, 245-246	4.1	
11	Myths and Misconceptions in the Management of Elderly Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2021 , 17, 415-419	0.7	
10	Incident Colorectal Cancer in Inflammatory Bowel Disease.. <i>Cancers</i> , 2022 , 14,	6.6	0
9	Ustekinumab Does Not Increase Risk of New or Recurrent Cancer in IBD Patients with Prior Malignancy.. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022 ,	4	1
8	Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.. <i>Gut</i> , 2021 ,	19.2	5
7	Solid extraintestinal malignancies in patients with inflammatory bowel disease.. <i>World Journal of Gastrointestinal Oncology</i> , 2021 , 13, 1956-1980	3.4	0
6	Crohn's Disease of the Elderly. <i>Gastroenterology Clinics of North America</i> , 2022 ,	4.4	1
5	Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. <i>CPT: Pharmacometrics and Systems Pharmacology</i> ,	4.5	0
4	Managing IBD in patients with previous cancers. <i>Frontline Gastroenterology</i> , 2022 , 13, e44-e50	2.6	1
3	ECCO Guidelines on Inflammatory Bowel Disease and Malignancies.		3

- 2 Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study. **2023**, Publish Ahead of Print, ○
- 1 Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease. 10, ○